MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1200/jco.2022.40.16_suppl.e21601
Abstract: BACKGROUND MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant to immune checkpoint inhibitors (ICI),… read more here.
Keywords: predictive response; checkpoint inhibitors; immune checkpoint; metastatic uveal ... See more keywords